ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
TRACON Pharmaceuticals Inc

TRACON Pharmaceuticals Inc (TCON)

1.43
0.00
(0.00%)
Closed July 21 4:00PM
0.00
0.00
(0.00%)

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
1.43
Bid
1.05
Ask
1.14
Volume
-
0.00 Day's Range 0.00
0.66 52 Week Range 14.746
Market Cap
Previous Close
1.43
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
180,459
Shares Outstanding
2,679,035
Dividend Yield
-
PE Ratio
-1.07
Earnings Per Share (EPS)
-1.34
Revenue
12.05M
Net Profit
-3.59M

About TRACON Pharmaceuticals Inc

TRACON Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its cost efficient, contract research organization (CRO) independent product development platform to partner with ex-U.S. companies to de... TRACON Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its cost efficient, contract research organization (CRO) independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States. The company's drug candidate includes Envafolimab, TRC102, TRC253, TJ4309, Bispecific Antibodies. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
1970
TRACON Pharmaceuticals Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker TCON. The last closing price for TRACON Pharmaceuticals was $1.43. Over the last year, TRACON Pharmaceuticals shares have traded in a share price range of $ 0.66 to $ 14.746.

TRACON Pharmaceuticals currently has 2,679,035 shares outstanding. The market capitalization of TRACON Pharmaceuticals is $3.83 million. TRACON Pharmaceuticals has a price to earnings ratio (PE ratio) of -1.07.

TCON Latest News

TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40.2117.21311475411.221.771.152090361.40947136CS
12-0.34-19.2090395481.772.10.661804591.45000607CS
26-1.608-52.92955892033.03814.7460.6620311866.84591979CS
52-4.75-76.86084142396.1814.7460.6624647925.18991173CS
156-98.97-98.5756972112100.4108.60.6690340310.08695218CS
260-10.168-87.670287980711.5982440.6675550233.47404026CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SERVServe Robotics Inc
$ 7.51
(185.55%)
262.73M
AUGXAugmedix Inc
$ 2.27
(147.71%)
21.87M
XCURExicure Inc
$ 0.5351
(76.02%)
14.02M
PSNLPersonalis Inc
$ 3.83
(56.33%)
22.76M
MDBHMDB Capital Holdings LLC
$ 10.675
(37.21%)
126.13k
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
124.61M
HYZNHyzon Motors Inc
$ 0.149
(-47.54%)
23.63M
MEDSTRxADE Health Inc
$ 14.92
(-33.45%)
223.27k
SILOSilo Pharma Inc
$ 2.50
(-27.95%)
11.93M
KITTNauticus Robotics Inc
$ 0.0935
(-27.46%)
28.43M
SERVServe Robotics Inc
$ 7.51
(185.55%)
262.73M
NVDANVIDIA Corporation
$ 117.93
(-2.61%)
206.41M
SXTP60 Degrees Pharmaceuticals Inc
$ 0.2602
(5.77%)
202.14M
SQQQProShares UltraPro Short QQQ
$ 8.46
(2.79%)
184.21M
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
119.98M

TCON Discussion

View Posts
davidsson10 davidsson10 3 weeks ago
https://www.globenewswire.com/news-release/2024/07/01/2906758/10391/en/TRACON-Pharmaceuticals-Announces-Termination-of-ENVASARC-Trial-and-Will-Explore-Strategic-Alternatives-Leveraging-its-In-House-Product-Development-Platform.html
👍️0
Renee Renee 3 weeks ago
TCON delisted from the Nasdaq to the OTC. PPS dropped from $1.77 to $1.09

https://otce.finra.org/otce/dailyList?viewType=Additions
👍️0
Monksdream Monksdream 2 months ago
TCON new 52 week low
👍️0
Gizzer211 Gizzer211 2 months ago
Old
👍️0
Monksdream Monksdream 3 months ago
TCON under $2
👍️0
Renee Renee 3 months ago
TCON: effective April 10,2024 a one for 20 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php
👍️0
kojak007 kojak007 4 months ago
ya thats my thought too. Thanks, all the best
👍️0
Tartiaboy Tartiaboy 4 months ago
I liquidated my position in TCON on the news. I don't see a path forward for TCON that is good for current shareholders. I will monitor TCON going forward from the sidelines.
👍️0
kojak007 kojak007 4 months ago
Hi Tartia,
I have no idea how this is possible. I guess its dead now. What do you think?

👍️0
axelvento axelvento 4 months ago
With a float of 26 million shares and a market cap of $23 million, TRACON operates within the realm of oncology research and development. Envafolimab, one of TRACON’s key assets, has garnered both Fast Track Designation and Orphan Drug Designation. Envafolimab, a novel PD-L1 antibody, is administered via subcutaneous injection, offering a convenient treatment approach.

The pivotal Phase 3 trial for Envafolimab, known as ENVASARC, is anticipated to provide updated safety and efficacy data by the end of the first quarter of 2024, with final data expected in the second half of the same year. The study design, presented at the American Society of Clinical Oncology (ASCO) in the previous year, outlines primary endpoints focused on objective response rate (ORR) confirmed by independent central review. The trial aims to assess Envafolimab’s efficacy, particularly in refractory undifferentiated pleomorphic sarcoma (UPS) or myxofibrosarcoma (MFS) patients, with an ORR confirmed by BICR with 9/80 objective responses needed to exclude the known < 5% ORR of pazopanib, the only agent approved for patients with refractory UPS or MFS.
👍️0
glenn1919 glenn1919 4 months ago
TCON..................................https://stockcharts.com/h-sc/ui?s=TCON&p=W&b=5&g=0&id=p86431144783
👍️ 1
Zardiw Zardiw 4 months ago
$TCON Chart from #DDAmanda - #1 Stock Screener :

Scans are preset. Push a Button. Find Winners Early:



Z
👍️0
Covid19freak Covid19freak 4 months ago
TCON $0.25 -interin data readout coming within days - market cap only $10 million
👍️0
Covid19freak Covid19freak 4 months ago
TCON $0.24 with buy rating check out link below
https://sih-st-charts.stocktwits-cdn.com/fit-in/500x0/filters:quality(75)/production/original_565125742.png
👍️0
oldstocks oldstocks 6 months ago
Nice to see these Pharmaceuticals go up today!
TCON up 15.38% regular trading close
JAGX hit .1362 in after hours, up from .1027 open
ATNM up 2.95%

52 week highs:
TCON $2.19
JAGX $5.08
ATNM $14.70
👍️0
TJG TJG 6 months ago
I only own AMRN and JAGX as my small cap ones. But am watching Tracon as I think they will get another order like the previous one that shot them up.
👍️0
oldstocks oldstocks 6 months ago
TCON needs to be over $1.124 by March 7th

To do that there has to be some good exciting news releases from now and then. The news would have to be so good that shorts would all want to cover.
The higher the stock runs the better chance it stays on NASDAQ

A reverse split is not going to get it there because there would be too few of outstanding shares.



As previously reported, on June 8, 2023, TRACON Pharmaceuticals, Inc. (the “Company”) received notices (the “Notices”) from Listing Qualifications staff of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that (i) for 30 consecutive business days preceding the date of the Notices, the market value of the Company’s common stock was less than $35.0 million, which does not meet the requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “Market Value Rule”) and the Company did not meet any of the alternative continued listing requirements set forth in Nasdaq Listing Rule 5550(b) (the “Financial and Liquidity Standards”), and (ii) for 30 consecutive business days preceding the date of the Notices, the closing bid price of the Company’s common stock was below $1.00 per share, which is the minimum required closing bid price for continued listing on the Nasdaq Capital Market pursuant to Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Company was provided 180 calendar days, or until December 5, 2023, to regain compliance with one of the Financial and Liquidity Standards and the Minimum Bid Price Requirement.

On December 12, 2023, the Company submitted a request for an oral appeal hearing before a Hearings Panel (the “Panel”). The hearing is scheduled to occur on March 7, 2024. Accordingly, the delisting and suspension of trading of the Company’s common stock described in the December 6 Notice will be stayed pending the issuance of the Panel’s final written decision. There can be no assurance that a favorable decision will be obtained from the Panel or that the Company will be successful in maintaining the listing of its common stock on the Nasdaq Capital Market.
👍️0
oldstocks oldstocks 6 months ago
TJ are you out of all stocks now?
I was just looking back at the old 8k's here.
I think this may have a chance for some news soon and maybe another spike but what do i know?
I can't predict news............
👍️0
TJG TJG 7 months ago
But the pre market has ended and the open market is not that impressed...
👍️0
TJG TJG 7 months ago
Big news out having a great pre market day
👍️0
TJG TJG 7 months ago
Nice day so far hopefully it holds these gains
👍️0
TJG TJG 8 months ago
Thats the goal... get settled back in at a dollar and then let all hell break loses...
👍️0
oldstocks oldstocks 8 months ago
It would be nice to see this get over $1
👍️ 1
YankeMike YankeMike 8 months ago
Yes, thanks. Good luck to us
👍️0
TJG TJG 8 months ago
Closed at .21 in after hours hopefully some news drops tomorrow. Nice buy you have as well. Another 3 million dollar contract drops and this will move by leaps and bounds.
👍️0
YankeMike YankeMike 8 months ago
Still have my shares I bought at $0.185 last week. Nice action today!
👍️0
TJG TJG 8 months ago
Hell of a lot of ASK slapping today.... raise your hand if you joined me in buying those17 at the end of last week and the start of this week... The rest of you just grab a Puffs Plus
👍️ 1
TJG TJG 8 months ago
Market it still creating a buying opp, there are a lot of folks that have not read the 8-K on this last $3,000,000.00 up front payment deal... a $20 a share Pharma company is not small potatoes and for them to want this product speaks volumes. Lots more to come based on just this one deal. So thanks for the cheapies who ever it was that pushed this down to the 17's


https://ih.advfn.com/stock-market/NASDAQ/tracon-pharmaceuticals-TCON/stock-news/92608567/form-8-k-current-report
👍️ 1
oldstocks oldstocks 8 months ago
TJ.. i posted this yesterday on another board
We bought TCON in hopes to make a profit.
I bought as high as .3089 and as low as .1862
I am not worried i am just waiting for the fluctuations. TCON is now heavily shorted.
They will have to buy back shares.

Tracon the company said it has licensed its proprietary PDP of CRO-independent clinical research to a clinical-stage biotech firm for a $3M upfront payment.

Latest news with Inhibrix is a big deal.

Under the deal, TRACON granted a non-exclusive and non-transferable license of its PDP to the clinical-stage biotech company for the design, conduct, and administration of clinical trials and related research and development activities, among others.
“We are now in a position to widely license our PDP to allow clinical-stage biotechnology and pharmaceutical companies to transform their clinical operations with the expectation of potentially dramatic cost reductions and shorter clinical trial timelines,” said CEO Charles Theuer.

About Inhibrix
Ticker INBX $20.54
$337 million in cash, so they have the money for the $3 Million deal.

https://inhibrx.com/wp-content/uploads/2023/11/Inhibrx-Presentation-Nov-2023.pdf

On November 17, 2023 (the “Effective Date”), Tracon Pharmaceuticals, Inc. (the “Company”) entered into a License Agreement (the “Agreement”) with Inhibrx, Inc. (“Inhibrx”). Under the terms of the Agreement, the Company granted a non-exclusive and non-transferable license of its product development platform to Inhibrx for the design, conduct and administration of clinical trials and related research and development activities, including activities relating to regulatory filings, submissions and approvals (the “Tracon PDP License”). The Tracon PDP License will allow Inhibrx to use the Company’s configuration documentation with a widely used software package in addition to use of the Company’s validation and qualification of the software package, and the Company’s standard operation procedure documents, policies, work instructions, and clinical operation templates (the “Licensed Technology”). Upon Inhibrx’s request during the first six months after the Effective Date, the Company is obligated to provide up to 500 hours of training (“Technical Support”) to Inhibrx. Pursuant to the Agreement, Inhibrx will make an upfront payment of $3.0 million to the Company, plus a potential $0.2 million (i) upon the completion of the Technical Support by the Company, or (ii) six months following the Company’s delivery of the Licensed Technology, whichever is earlier.
👍️0
YankeMike YankeMike 8 months ago
Thanks for the info
👍️ 1
TJG TJG 8 months ago
Not sure how many have seen the 8 K that was filed to go along with the PR on the $3,000,000 contract but this is the company that bought the PDL licensee from TRACON Pharmaceuticals Inc. They are a $20.00 a share NASDAQ stock. This is not a micro cap Pinksheet stock its a $900 million dollar market cap company.

https://ih.advfn.com/stock-market/NASDAQ/tracon-pharmaceuticals-TCON/stock-news/92608567/form-8-k-current-report

https://inhibrx.com/investors/
👍️0
Copilotdog Copilotdog 8 months ago
Charles will split and dilute. He’s a pos.
👍️0
oldstocks oldstocks 8 months ago
I just bought more before after market close.
Never know which direction this could go from here.
To cheap at this level.
👍️0
TJG TJG 8 months ago
Good thing about Etrade is you can put a pre market order in and it will stall all day and up till 8 pm if you so choose...
👍️0
oldstocks oldstocks 8 months ago
I had a buy order in the 17's in the AM market and I wasn't following it and the order automatically expired when the regular market opened
👍️0
TJG TJG 8 months ago
Some Thanksgiving selling, very typical with this level of stocks...also a very nice buying opp for those that can see past two or three days in advance... doubled my holdings in those 17's which was just where my original buy in was.
👍️0
oldstocks oldstocks 8 months ago
The 8am had a little spike and pulled back.
I am not worried about price decline.
It tends to pop later or another day.
👍️0
TJG TJG 8 months ago
Well pre market is not doing us any favors down over 2 cents so far and we have yet to hit the real premarket trading which starts at 8 am

Most likely are good buying opp will come out of this morning
👍️0
81vette 81vette 8 months ago
Lots of vol pre-mkt,could see gap up if hc wainwright paid promo shares are finally gone,(that analyst co is horrible,they shouldn’t be able to call themselves analysts,all they do is put $7 on everything and get tons of shares and dump them until gone)
👍️0
YankeMike YankeMike 8 months ago
Yes, it looks promising!
👍️0
rayank rayank 8 months ago
A lot in the pipeline: "TRACON Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of targeted therapeutics for cancer. The Company’s lead product candidate, envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma. The Company’s other product candidates are YH001, a CTLA-4 antibody that is in Phase I/II development for the treatment of sarcoma; TRC102, a small molecule that is in Phase II clinical development for the treatment of mesothelioma; TJ004309, a CD73 antibody that is in Phase I testing, that is being developed through a collaboration with I-Mab Biopharma, and multiple bispecific antibody programs in preclinical development that are being developed through a collaboration with I-Mab Biopharma. The Company offers partners a solution for the clinical development and commercialization of their products in the United States."
smile
👍️ 2
rayank rayank 8 months ago
Volume(Heavy Day) 73,872,965 November 21, 2023 3:59pm ET
👍️ 1
81vette 81vette 8 months ago
$15m traded today,gaining enough interest to have a sleepover for me
👍️ 1
81vette 81vette 8 months ago
Big orders slapping,some $15k,inst./whales?,gotta love big solid green candles as power hour approaches
👍️ 1
81vette 81vette 8 months ago
30% institutional,inst. controls 80% of entire mkt moves.follow the $ is a saying for a good reason.I doubt the blackrock crooked mms gonna destroy this,I could be wrong but it is optionable,contracts can suck for retail,holding up great so far and huge short to cover yet.support yesterday was sma200(5min) currently.1834 we getting close now
👍️0
81vette 81vette 8 months ago
7m cash on hand,only 1m debt,no offering needed,1st of many contracts,3m contract on a 5m mkt cap,adjustment inbound,pps headed over $1 so no r/s needed.
👍️0
81vette 81vette 8 months ago
TCON biz model is genius,during a gold rush sell pics/axes/shovels/maps/teach ppl how to pan,guarantee $ in bank!!
👍️ 1
81vette 81vette 8 months ago
Expect mid day vol surge soon
👍️0
Wallstveteran Wallstveteran 8 months ago
tcon featured in article!
https://stockmarketcoffee.com/top-3-hottest-stocks-trading-today-under-5/
👍️ 1 🤑 1
TJG TJG 8 months ago
I am impressed with this volume as its also taking place during the worst trading week of the year... Thanksgiving week is notorious for people dumping for a long weekend and then coming back in on the following Monday... For a stock that was at .12 not that long ago one has to expect profit taking to happen... its whats going to happen in the next couple of weeks that I am excited about.
👍️0

Your Recent History

Delayed Upgrade Clock